73933-19-4

Basic information

• Product Name: (4-BENZYL-MORPHOLIN-2-YL)-ACETIC ACID ETHYL ESTER
• Synonyms: BZL-MORPH-2-ACOET;ETHYL 2-(4-BENZYLMORPHOLIN-2-YL)ACETATE;(4-BENZYL-MORPHOLIN-2-YL)-ACETIC ACID ETHYL ESTER;N-BENZYL-MORPHOLINE-2-YL-ACETIC ACID ETHYL ESTER, RACEMATE;ethyl (4-benzylmorpholin-2-yl)acetate;N-Benzyl-2-ethoxycarbonylMethylMorpholine;2-Morpholineacetic acid, 4-(phenylMethyl)-, ethyl ester
• CAS NO: 73933-19-4
• Molecular Formula: C₁₅H₂₁NO₃
• Molecular Weight: 263.33
• Mol File: 73933-19-4.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 349.144 °C at 760 mmHg
• Flash Point: 164.957 °C
• Appearance: /
• Density: 1.093 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.519
• Storage Temp.: 2-8°C
• PKA: 6.25±0.10(Predicted)
• CAS DataBase Reference: (4-BENZYL-MORPHOLIN-2-YL)-ACETIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (4-BENZYL-MORPHOLIN-2-YL)-ACETIC ACID ETHYL ESTER(73933-19-4)
• EPA Substance Registry System: (4-BENZYL-MORPHOLIN-2-YL)-ACETIC ACID ETHYL ESTER(73933-19-4)

Safety Data

• Hazardous Substances Data: 73933-19-4(Hazardous Substances Data)

Usage

General Description

(4-Benzyl-morpholin-2-yl)-acetic acid ethyl ester is a chemical compound with the molecular formula C16H21NO3. It is an ester derivative of (4-benzyl-morpholin-2-yl)-acetic acid, which is a synthetic organic compound with potential analgesic and anti-inflammatory properties. This chemical has the potential to be used in pharmaceutical or medical research for the development of new drugs. It is important to handle and store this compound with care due to its potential health hazards and irritant properties.

InChI:InChI=1/C15H21NO3/c1-2-18-15(17)10-14-12-16(8-9-19-14)11-13-6-4-3-5-7-13/h3-7,14H,2,8-12H2,1H3

Upstream product

• 104-63-2 N-Benzylethanolamine 
• 37746-78-4 4-bromo-trans-crotonic acid ethyl ester 
• 6065-32-3 4-bromocrotonic ethyl ester 

Downstream Products

• 1398371-20-4 2-(4-(2-(2-(((R)-1-(naphthalen-1-yl)ethyl)amino)ethyl)morpholino)phenoxy)acetic acid 
• 1005474-71-4 tert-butyl 2-(2-(tosyloxy)ethyl)morpholine-4-carboxylate 
• 766539-28-0 2-(4-(tert-butoxycarbonyl)morpholin-2-yl)acetic acid 
• 1398495-52-7 4-((2-(2-(((R)-1-(naphthalen-1-yl)ethyl)amino)ethyl)morpholino)methyl)benzoic acid 
• 1398495-34-5 2-(4-(2-(2-(((R)-1-(naphthalen-1-yl)ethyl)amino)ethyl)morpholino)phenoxy)acetic acid 
• 112887-43-1 2-(2-hydroxyethyl)-4-benzylmorpholine 
• 126645-68-9 4-amino-N-[2-(4-benzyl-2-morpholinyl)ethyl]-5-chloro-2-methoxybenzamide 
• 112914-08-6 2-(2-aminoethyl)-4-benzylmorpholine 
• 126645-69-0 4-amino-N-[2-(4-benzyl-2-morpholinyl)ethyl]-5-chloro-2-ethoxybenzamide 
• 126645-72-5 N-<2-(4-benzyl-2-morpholinyl)ethyl>phthalimide 
• 146944-29-8 4-benzyl-2-(((ethoxycarbonyl)amino)methyl)morpholine 
• 135072-27-4 4-benzyl-2-(carbamoylmethyl)morpholine 

Relevant articles and documents

INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE

Bifunctional compounds, which find utility as modulators of leucine-rich repeat kinase 2 (LRRK2), are described herein. In particular, the hetero-bifunctional compounds of the present disclosure contain on one end a moiety that binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds LRRK2, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The hetero-bifunctional compounds of the present disclosure exhibit a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aberrant regulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

BENZO[B]FURANS AS BROMODOMAIN INHIBITORS

The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy.

SUBSTITUTED MORPHOLINES AS MODULATORS FOR THE CALCIUM SENSING RECEPTOR

Compounds of Formula (I) along with processes for their preparation that are useful for treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of calcium sensing (CaSR) receptors. Methods of treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of calcium sensing (CaSR) receptors of Formula (I).